Longevity Biotech
Dr Sinha. has extensive experience in discovery and preclinical development of small molecules involved in the pathogenesis of cardiovascular and inflammatory diseases. Dr. Sinha currently splits time between BridgeBio and Longevity Biotech. She is the former Chief Scientific Officer of Global Blood Therapeutics . Previously, she was Vice President, Head of Biology at Portola Pharmaceuticals and had held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. She is a co-inventor of andexanet alfa, a first in class recombinant protein currently awaiting FDA approval.
This person is not in any offices
Longevity Biotech
Longevity Biotech is developing a new class of therapeutic candidates called Hybridtides. Their focus is on delivering clinically transformative products that tackle the most challenging aspects of medicine today.